- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03433222
Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III
EBIRE: Phase 1 Study of High Fluence LED-Red Light in Fitzpatrick Skin Types I to III
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The effects of visible light, while common in the environment (visible spectrum accounts for 44% of total solar energy), remain undefined. An important safety feature of visible red light (600 nm to 700 nm) is that it does not generate pro-carcinogenic DNA damage as does ultraviolet (UV) light. Recently published clinical observations indicate that red light in combination with other modalities such as photosensitizers in combined red light photodynamic therapy can treat skin diseases. However, preliminary in vitro data generated by the investigator's research group suggests that red light can function as a stand-alone treatment, eliminating the side-effects of chemical photosensitizers and the potential long-term harm of current UV therapy. Furthermore, commercially available light emitting diode-red light (LED-RL) units exist and are already FDA-cleared for other dermatological uses (such as rhytides and acne), thus clinical translation for use in skin diseases could occur relatively quickly following safety and efficacy demonstration. Developing high fluence LED-RL phototherapy as a treatment for skin conditions may represent an important advance that lacks the serious systemic side effects associated with immunomodulatory agents (such as oral steroids); avoids the need for invasive, painful injections with anti-fibrotic agents (such as intralesional steroids, 5-fluorouracil and bleomycin); and eliminates the UV-induced DNA damage associated with skin cancer and photoaging that are associated with current UVA/UVA1 and UVB/narrowband UVB phototherapy. To the investigator research group's knowledge, no clinical trials have been performed to determine the safety of high fluence LED-RL in different Fitzpatrick skin types. The innovation of this approach is that the investigator research group intend to study the safety of high fluence LED-RL in Fitzpatrick skin types I to III (based on NIH's race/ethnicity category of non-Hispanic, Caucasian).
A previous study demonstrated that fluence up to 320 J/cm2 is safe for all skin types (unpublished data, investigator research group). This study will evaluate doses of 480 J/cm2 and 640 J/cm2 in Fitzpatrick skin types I to III. This is based on the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2 which is the maximum recommended starting dose in clinical studies, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2).
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Mather, California, United States, 95655
- Recruiting
- Sacramento VA Medical Center
-
Contact:
- Jared Jagdeo, MD, MS
- Phone Number: 916-451-7245
- Email: Jared.Jagdeo@va.gov
-
Contact:
- Erica Wang, MD
- Email: Erica.Wang2@va.gov
-
Principal Investigator:
- Jared Jagdeo, MD, MS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects of any sex and age
- Non-Hispanic, Caucasian race/ethnicity
- Nondominant proximal anterior forearm is wide enough to ensure reproducible placement of LED-RL phototherapy or mock therapy hand-held unit
- Available and willing to attend all clinic visits
- Able and willing to give informed consent
Exclusion Criteria:
- Subjects using any photosensitizers (i.e. lithium, melatonin, phenothiazine antipsychotics, antibiotics)
- Subjects with diabetes mellitus (DM)
- Subjects with a history of skin cancer.
- Subjects with systemic lupus erythematous (SLE)
- Subjects with light-sensitive conditions (All subjects will be tested for photosensitivity per manufacturer user guide instructions)
- Subjects with open wounds on the nondominant proximal anterior forearm
- Subjects with fibrotic skin disease or other skin conditions on the nondominant proximal anterior forearm
- Subjects with tattoos that cover the procedure site on the nondominant proximal anterior forearm
- Subjects of an ethnic race group other than Non-Hispanic, Caucasian
- Subjects who have previously participated in the VA Northern California's "Phase 1 Study of LED-RL in Human Skin"
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HF-LED-RL Phototherapy
The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy). After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event. |
The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance. All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.
Other Names:
|
SHAM_COMPARATOR: Mock Therapy
The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy). After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event. |
Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL. All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: 3 consecutive weeks
|
The primary objective is to determine the maximum tolerated dose.
|
3 consecutive weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of safety profile by evaluating incidence of procedure-related common procedure outcomes
Time Frame: 3 consecutive weeks
|
To evaluate safety of high fluence LED-RL phototherapy by recording any common expected procedure outcomes [warmth, erythema (redness), and edema (swelling) that are mild, self-limited, and are expected to last less than 24 hours] via assessment during and immediately post-procedure and subject diary of adverse events.
|
3 consecutive weeks
|
Assessment of safety profile by evaluating incidence of adverse events
Time Frame: 3 consecutive weeks
|
To evaluate safety of high fluence LED-RL phototherapy by recording adverse events (including: first-degree or higher skin burning or blistering, erythema lasting more than 24 hours, severe swelling, pain, ulceration, change in sensation, and/or muscle weakness], via assessment during and immediately post-procedure and subject diary of adverse events.
|
3 consecutive weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jared Jagdeo, MD, MS, Physician, Dermatology
Publications and helpful links
General Publications
- Jagdeo JR, Adams LE, Brody NI, Siegel DM. Transcranial red and near infrared light transmission in a cadaveric model. PLoS One. 2012;7(10):e47460. doi: 10.1371/journal.pone.0047460. Epub 2012 Oct 15.
- Mamalis A, Jagdeo J. Light-emitting diode-generated red light inhibits keloid fibroblast proliferation. Dermatol Surg. 2015 Jan;41(1):35-9. doi: 10.1097/01.DSS.0000452650.06765.51.
- Sadick NS. A study to determine the efficacy of a novel handheld light-emitting diode device in the treatment of photoaged skin. J Cosmet Dermatol. 2008 Dec;7(4):263-7. doi: 10.1111/j.1473-2165.2008.00404.x.
- Sadick NS. Handheld LED array device in the treatment of acne vulgaris. J Drugs Dermatol. 2008 Apr;7(4):347-50.
- Lev-Tov H, Mamalis A, Brody N, Siegel D, Jagdeo J. Inhibition of fibroblast proliferation in vitro using red light-emitting diodes. Dermatol Surg. 2013 Aug;39(8):1167-70. doi: 10.1111/dsu.12212. Epub 2013 Apr 16.
- Ho D, Kraeva E, Wun T, Isseroff RR, Jagdeo J. A single-blind, dose escalation, phase I study of high-fluence light-emitting diode-red light (LED-RL) on human skin: study protocol for a randomized controlled trial. Trials. 2016 Aug 2;17:385. doi: 10.1186/s13063-016-1518-7.
- Wang EB, Kaur R, Nguyen J, Ho D, Austin E, Maverakis E, Li CS, Hwang ST, Isseroff RR, Jagdeo J. A single-blind, dose-escalation, phase I study of high-fluence light-emitting diode-red light on Caucasian non-Hispanic skin: study protocol for a randomized controlled trial. Trials. 2019 Mar 20;20(1):177. doi: 10.1186/s13063-019-3278-7.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-01-00804
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrosis
-
San Gerardo HospitalCompletedIdiopathic Pulmonary Fibrosis | Cardiac Fibrosis | Arterial FibrosisItaly
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Assistance Publique - Hôpitaux de ParisRecruitingIdiopathic Retroperitoneal FibrosisFrance
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
University of ParmaUnknownIdiopathic Retroperitoneal Fibrosis | Perianeurysmal Retroperitoneal Fibrosis | Chronic PeriaortitisItaly
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University Hospital, GrenobleNot yet recruiting
Clinical Trials on HF-LED-RL Phototherapy
-
State University of New York - Downstate Medical...CompletedFibrosis | Scar | Keloid | Skin Wound | Hypertrophic Scar | Skin ScarringUnited States
-
GE HealthcareCompleted
-
Henry Ford Health SystemWithdrawn
-
Fatima Jinnah Medical UniversityCompleted
-
Aparecida Maria CataiFundação de Amparo à Pesquisa do Estado de São PauloUnknownType 2 Diabetes MellitusBrazil
-
Erebouni Medical CenterRecruitingNeonatal Hyperbilirubinemia | Jaundice, NeonatalArmenia
-
Institute of Biophysics and Cell Engineering of...Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyCompletedTreatment of Patients With Non-healing Wounds and Trophic Ulcers Using Autologous Dermal FibroblastsNon-healing Wound | Trophic Ulcer | Non-Healing Ulcer of SkinBelarus
-
Professor Fernando Figueira Integral Medicine InstituteUnknownNeonatal HyperbilirubinemiaBrazil
-
Jared Jagdeo, MD, MSVA Northern California Health Care System; East Bay Institute for Research...CompletedFibrosis | Cicatrix | Scar | Injuries | Wounds | Keloid | Hypertrophic | ScarringUnited States
-
Hermano Miguel FoundationCompletedSprains and Strains | Tendinopathy | Fasciitis | Epicondylitis | Muscle SpasmEcuador